Dihexa vs FGL
Emerging vs Limited Research
compatible Different mechanisms of cognitive support; Dihexa acts via HGF/c-Met while FGL activates FGFR1.
Molecular Data
Dihexa FGL
Weight 504.7 Da ~1500 Da
Half-life 8-12 days Not well characterized
Type Modified oligopeptide Synthetic peptide derived from the second fibronectin type III module of NCAM
Key Benefits
Dihexa
01 Dramatic synaptogenesis promotion
02 10 million times more potent than BDNF
03 Cognitive enhancement and memory improvement
04 Neuroprotection and potential neuroregeneration
05 Applications for Alzheimer's, TBI, age-related cognitive decline
06 Oral bioavailability
FGL
01 Activates FGFR1 to promote synaptic plasticity
02 Stimulates hippocampal neurogenesis
03 Provides neuroprotection against excitotoxic and ischemic injury
04 Enhances long-term potentiation (LTP) in preclinical models
05 Potential cognitive enhancement via NCAM-mimetic signaling
Dosing Protocols
Dihexa
8-10mg oral or 2-5mg injectable (0.5mg/kg based on research) / Once daily in the morning
Research protocol 0.5mg/kg daily Daily or 3x weekly
Standard injectable 2-5mg total 1x daily
FGL
100-200mcg per day / 1x daily
Cognitive support (research protocol) 100-200mcg 1x daily
Side Effects
Dihexa
Headaches (most frequent side effect)
Anxiety or overstimulation
Sleep disruption when dosed late in day
Mental clarity increase
FGL
Injection site reactions (redness, mild swelling, irritation)
Contraindications
Not FDA approved - research compound only
Theoretical cancer risk via c-Met activation
Cancer history (avoid due to c-Met pathway)
Pregnancy or breastfeeding
No long-term human safety data
Pregnancy or breastfeeding
Known peptide or NCAM-related compound allergies
Very limited human safety data -- use with caution under medical supervision
Research Evidence
Dihexa FGL
Status Emerging Limited Research
References 4 studies 4 studies
Latest 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.